Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Fennec Pharmaceuticals Inc FENC
$10.61
▼ -0.14%
($-0.02)
Open
$10.53
Prev Close
$10.62
Day Range
$10.51 – $10.81
52W Range
$5.65 – $13.25
Market Cap
$371.89M
Beta
1.28
EPS (TTM)
$-0.12
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2001-06-05 |
| Shares Out. | 34,740,000 |
| Website | fennecpharma.com/ ↗ |
| Phone | 19196364530 |
| Employees | 35 |
| Revenue | $17.9M |
| Gross Profit | $17.2M |
| Net Income | $2.0M |
| Free Cash Flow | -$2.0M |
| Total Assets | $75.8M |
| Total Liabilities | $33.3M |
| Equity | $42.4M |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Fennec Pharmaceuticals Inc is a publicly traded company under the ticker symbol FENC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)